UK will be ‘less attractive’ for clinical research post Brexit
More than half of US biotech executives believe that the UK will be a ‘less attractive’ country for conducting clinical trials after Brexit, indicates new research.
Read More
Tag: Executives
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
